These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 8439390)
1. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. Tohgi H; Abe T; Takahashi S J Neural Transm Park Dis Dement Sect; 1993; 5(1):27-34. PubMed ID: 8439390 [TBL] [Abstract][Full Text] [Related]
2. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. Tohgi H; Abe T; Takahashi S; Takahashi J; Ueno M; Nozaki Y Neurosci Lett; 1990 Aug; 116(1-2):194-7. PubMed ID: 2259448 [TBL] [Abstract][Full Text] [Related]
3. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension. Lamotte G; Holmes C; Sullivan P; Goldstein DS Clin Auton Res; 2019 Feb; 29(1):113-117. PubMed ID: 30229336 [TBL] [Abstract][Full Text] [Related]
4. Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes. Tohgi H; Abe T; Takahashi S; Takahashi J; Nozaki Y; Ueno M; Kikuchi T J Neural Transm Park Dis Dement Sect; 1993; 5(1):17-26. PubMed ID: 8094960 [TBL] [Abstract][Full Text] [Related]
5. Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine. Ogawa N; Kuroda H; Yamamoto M; Nukina I; Ota Z Acta Med Okayama; 1984 Jun; 38(3):301-4. PubMed ID: 6431755 [TBL] [Abstract][Full Text] [Related]
6. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease. Yamamoto M; Ogawa N; Ujike H J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714 [TBL] [Abstract][Full Text] [Related]
7. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease. Ogawa N; Yamamoto M; Takayama H J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472 [TBL] [Abstract][Full Text] [Related]
8. Effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) on catecholamine levels in plasma and cerebrospinal fluid (CSF) in anesthetized rats. Ishikawa Y; Kato Y; Murakami Y; Inoue T; Koshiyama H; Imura H Proc Soc Exp Biol Med; 1987 Feb; 184(2):197-200. PubMed ID: 3101067 [TBL] [Abstract][Full Text] [Related]
11. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients. Maruyama W; Naoi M; Narabayashi H J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986 [TBL] [Abstract][Full Text] [Related]
12. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. Goldstein DS; Holmes C; Sewell L; Pechnik S; Kopin IJ J Clin Pharmacol; 2011 Jan; 51(1):66-74. PubMed ID: 20220040 [TBL] [Abstract][Full Text] [Related]
13. L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients. Yoshida M; Noguchi S; Kuramoto S Kurume Med J; 1989; 36(2):67-74. PubMed ID: 2511378 [TBL] [Abstract][Full Text] [Related]
14. DL-threo-DOPS as a precursor of noradrenaline. Reches A; Jackson-Lewis V; Fahn S Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):202-8. PubMed ID: 3937060 [TBL] [Abstract][Full Text] [Related]
15. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study. Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731 [TBL] [Abstract][Full Text] [Related]
16. Effects of L-threo-3,4-dihydroxyphenylserine on efflux of monoamines and acetylcholine in guinea pig brain. Nishino N; Fujii Y; Kondo M; Shuntoh H; Fujiwara H; Tanaka C J Pharmacol Exp Ther; 1987 Aug; 242(2):621-8. PubMed ID: 3112367 [TBL] [Abstract][Full Text] [Related]
17. Dopamine/L-dopa ratio in cerebrospinal fluid of parkinsonian patients treated with L-dopa + benserazide. Fekete M; Tárczy M; Bihari K; Katona G Psychopharmacology (Berl); 1984; 82(1-2):93-4. PubMed ID: 6420835 [TBL] [Abstract][Full Text] [Related]
18. Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain. Comparison with that of L-dopa. Kato T; Karai N; Katsuyama M; Nakamura M; Katsube J Biochem Pharmacol; 1987 Sep; 36(18):3051-7. PubMed ID: 3115271 [TBL] [Abstract][Full Text] [Related]
19. The effects of L-threo-dihydroxyphenylserine on norepinephrine metabolism in rat brain. Semba J; Takahashi R Psychiatry Res; 1985 Aug; 15(4):319-26. PubMed ID: 3934694 [TBL] [Abstract][Full Text] [Related]
20. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. Bartholini J; Constantinidis J; Puig M; Tissot R; Pletscher A J Pharmacol Exp Ther; 1975 May; 193(2):523-32. PubMed ID: 1142103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]